Cushing's Syndrome clinical trials at UC Health
1 research study open to eligible people
Showing trials for
A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome
open to eligible people ages 18-80
This is a Phase 3, double-blind, placebo-controlled, randomized-withdrawal study to assess the efficacy, safety and pharmacokinetics (PK) of relacorilant in patients with endogenous Cushing syndrome and concurrent type 2 diabetes mellitus/impaired glucose tolerance and/or uncontrolled hypertension
at UCLA
Last updated: